Schrodinger (NASDAQ:SDGR) vs. Aclarion (NASDAQ:ACON) Critical Review

Aclarion (NASDAQ:ACON) and Schrodinger (NASDAQ:SDGR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aclarion and Schrodinger, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Schrodinger	1	2	4	1	2.62

Aclarion presently has a consensus target price of $7.50, indicating a potential upside of 331.03%. Schrodinger has a consensus target price of $25.83, indicating a potential downside of 9.42%. Given Aclarion’s higher probable upside, equities research analysts clearly believe Aclarion is more favorable than Schrodinger.

Risk & Volatility

Aclarion has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aclarion and Schrodinger”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	62.64	-$7.23 million	($7.40)	-0.24
Schrodinger	$255.87 million	8.23	-$103.26 million	($0.74)	-38.54

Aclarion has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aclarion and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Schrodinger	-20.98%	-16.37%	-8.19%

Institutional & Insider Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 79.0% of Schrodinger shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Schrodinger beats Aclarion on 11 of the 15 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.